<DOC>
	<DOCNO>NCT02545933</DOCNO>
	<brief_summary>Dual antiplatelet therapy ( DAPT ) aspirin P2Y12 receptor inhibitor represent standard care long-term secondary prevention atherothrombotic event patient myocardial infarction ( MI ) . However , rate ischemic recurrence remain high , may part due fact platelet signal pathway , thrombin-induced platelet aggregation , continue activate . Vorapaxar protease-activated receptor ( PAR ) -1 inhibitor , exert potent inhibition thrombin-mediated platelet aggregation . It approve clinical use Food Drug Administration reduction thrombotic cardiovascular event patient history MI peripheral arterial disease . However , date clinical trial experience vorapaxar almost exclusively P2Y12 receptor inhibitor clopidogrel effect vorapaxar combination antiplatelet therapy include prasugrel ticagrelor , largely unexplored . Further , role vorapaxar part dual antithrombotic treatment regimen , addition novel P2Y12 receptor inhibitor , withdrawal aspirin , represent another important area clinical interest potential maximize ischemic protection reduce risk bleeding . The propose prospective , randomize , parallel-design , open label , study conduct real world clinical set post-MI patient aim assess pharmacodynamic effect vorapaxar addition antiplatelet therapy novel P2Y12 receptor inhibitor ( prasugrel ticagrelor ) without aspirin .</brief_summary>
	<brief_title>Vorapaxar Patients With Prior Myocardial Infarction Treated With Prasugrel Ticagrelor</brief_title>
	<detailed_description>Dual antiplatelet therapy ( DAPT ) aspirin P2Y12 receptor inhibitor represent standard care long-term secondary prevention atherothrombotic event patient myocardial infarction ( MI ) . The novel P2Y12 receptor inhibitor prasugrel ticagrelor characterize prompt , potent , predictable antiplatelet effect compare clopidogrel associate great reduction ischemic event acute coronary syndrome patient . However , rate ischemic recurrence remain high , may part due fact platelet signal pathway , thrombin-induced platelet aggregation , continue activate . Vorapaxar novel , orally active , competitive slowly reversible protease-activated receptor ( PAR ) -1 inhibitor , exert potent inhibition thrombin-mediated platelet aggregation . It approve clinical use Food Drug Administration reduction thrombotic cardiovascular event patient history MI peripheral arterial disease . A large-scale clinical trial show use vorapaxar ( 2.5 mg once/daily ) addition standard antiplatelet therapy ( include aspirin P2Y12 receptor inhibitor ) effective secondary prevention recurrent thrombotic event patient previous atherothrombosis , particular patient prior MI , expense increase major bleeding . However , date clinical trial experience vorapaxar almost exclusively P2Y12 receptor inhibitor clopidogrel effect vorapaxar combination state-of-the-art antiplatelet therapy post-MI setting , include prasugrel ticagrelor , largely unexplored . This may indeed represent limitation uptake vorapaxar modern day clinical practice agent broadly utilized . Further , role vorapaxar part dual antithrombotic treatment regimen , addition novel P2Y12 receptor inhibitor , withdrawal aspirin , represent another important area clinical interest potential maximize ischemic protection reduce risk bleeding . The propose prospective , randomize , parallel-design , open label , study conduct real world clinical set post-MI patient aim assess pharmacodynamic effect vorapaxar addition antiplatelet therapy novel P2Y12 receptor inhibitor ( prasugrel ticagrelor ) without aspirin . Pharmacodynamic assessment perform multiple time point different assay explore multiple pathway platelet aggregation . Exploratory assessment safety approach also evaluate .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients prior MI within previous 2 week 12 month . 2 . On DAPT lowdose aspirin ( 81mg od ) either prasugrel ( 10mg od ) ticagrelor ( 90mg bid ) per standardofcare least 2 week . 3 . Free bleed ischemic event index MI event . 4 . Age 18 75 year old . Exclusion criterion : 1 . History stroke , transient ischemic attack , intracranial hemorrhage . 2 . Active pathological bleeding , history bleed event increase risk bleeding . 3 . Known severe hepatic impairment . 4 . Age &gt; 75 year . 5 . Body weight &lt; 60 Kg . 6 . Use strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole , posaconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , boceprevir , telaprevir , telithromycin conivaptan ) inducer ( e.g. , rifampin , carbamazepine , St. John 's Wort phenytoin ) . 7 . On treatment oral anticoagulant ( vitamin K antagonist , dabigatran , rivaroxaban , apixaban , edoxaban ) . 8 . On treatment antiplatelet agent aspirin , prasugrel ticagrelor past 14 day . 9 . Creatinine clearance &lt; 30 mL/minute . 10 . Platelet count &lt; 80x106/mL 11 . Hemoglobin &lt; 10g/dL 12 . Hemodynamic instability 13 . Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>vorapaxar</keyword>
</DOC>